Logo

American Heart Association

  2
  0


Final ID: Su3141

Circulating Ketone Bodies, Lipoprotein(a) and Incident Cardiovascular Outcomes and Mortality: Insights from The UK Biobank

Abstract Body (Do not enter title and authors here): Background: Lipoprotein(a) [Lp(a)] is an independent risk factor for atherosclerotic cardiovascular disease (ASCVD). Recent epidemiological studies have revealed an association between ketone bodies (KB) and adverse cardiovascular outcomes, offering a unique insight into metabolic health and its impact on mortality risk. Elevated levels of both Lp(a) and KB may synergistically amplify pathological processes, including endothelial dysfunction, inflammation, and oxidative stress, through their involvement in shared pathophysiological pathways, thereby exacerbating disease progression beyond the impact of each biomarker individually.
Methods: Utilizing data from the UK Biobank, KB were measured by nuclear magnetic resonance spectroscopy and serum Lp(a) concentrations were measured using an immunoturbidimetric assay. Four groups were created as follows: Group 1: Lp(a)<125 nmol/L and Total KB<75th percentile (<94 μmol/L); Group 2: Lp(a)≥125 nmol/L and Total KB<75th percentile; Group 3: Lp(a)<125 nmol/L and Total KB≥75th percentile; and Group 4: Lp(a)≥125 nmol/L and Total KB≥75th percentile. Multivariable-adjusted Cox proportional hazard models were used to examine the association of Lp(a) and total KB with incident cardiovascular outcomes and mortality.
Results: A total of 72,704 UK Biobank participants (mean age 56 y, SD=8, 55% women) without prevalent CVD or HF with a median follow up of 13.4 years were included. In the fully adjusted model, compared with those in the reference group (Group 1), participants in Group 2, Group 3, and Group 4 demonstrated a 14%, 17%, and 38%, increased risk of incident ASCVD events, respectively (p<0.01 for all). However, those with Lp(a) ≥ 125 nmol/L and total KB < 75th percentile demonstrated no increased risk of HF, all-cause mortality, stroke, or CVD mortality. Participants with elevated levels of both Lp(a) and KB had significantly increased risk of all outcomes (Table). There was no evidence for a statistically significant interaction between Lp(a) and KB on any outcome.
Conclusion: Consistent with prior literature, Lp(a) was associated with atherosclerotic outcomes. However, elevated KB was associated with all outcomes, irrespective of Lp(a) levels.
  • Chevli, Parag  ( Wake Forest University School of Medicine , Winston Salem , North Carolina , United States )
  • Mirzai, Saeid  ( Wake Forest University SOM , Winston Salem , North Carolina , United States )
  • Kazibwe, Richard  ( Wake Forest University , Winston Salem , North Carolina , United States )
  • Rikhi, Rishi  ( Wake Forest University School of Medicine , Winston Salem , North Carolina , United States )
  • Bhatia, Harpreet  ( University of California San Diego , San Diego , California , United States )
  • Slipczuk, Leandro  ( Montefiore Medical Center , Bronx , New York , United States )
  • Gianos, Eugenia  ( Lenox Hill- Northwell Health , New York , New York , United States )
  • Pagidipati, Neha  ( DCRI , Durham , North Carolina , United States )
  • Shapiro, Michael  ( Wake Forest Univ School of Medicine , Winston Salem , North Carolina , United States )
  • Author Disclosures:
    Parag Chevli: DO NOT have relevant financial relationships | Saeid Mirzai: DO NOT have relevant financial relationships | Richard Kazibwe: DO NOT have relevant financial relationships | Rishi Rikhi: DO NOT have relevant financial relationships | Harpreet Bhatia: DO have relevant financial relationships ; Consultant:Kaneka:Past (completed) ; Advisor:Arrowhead:Active (exists now) ; Advisor:Abbott:Active (exists now) ; Advisor:Novartis:Active (exists now) ; Consultant:Novartis:Active (exists now) | Leandro Slipczuk: DO have relevant financial relationships ; Research Funding (PI or named investigator):Philips:Active (exists now) ; Research Funding (PI or named investigator):Amgen:Active (exists now) | Eugenia Gianos: DO have relevant financial relationships ; Speaker:Kaneka:Past (completed) ; Speaker:Medaxiom:Past (completed) | Neha Pagidipati: DO have relevant financial relationships ; Research Funding (PI or named investigator):Alnylam:Active (exists now) ; Consultant:Merck:Past (completed) ; Consultant:AstraZeneca:Active (exists now) ; Consultant:Esperion:Active (exists now) ; Consultant:Eli Lilly:Active (exists now) ; Consultant:CRISPR Therapeutics:Active (exists now) ; Consultant:Boehringer Ingelheim:Active (exists now) ; Consultant:Bayer:Past (completed) ; Research Funding (PI or named investigator):Merck:Active (exists now) ; Other (please indicate in the box next to the company name):Novo Nordisk - research + consultant:Active (exists now) ; Other (please indicate in the box next to the company name):Novartis - research + consultant:Active (exists now) ; Research Funding (PI or named investigator):Eli Lilly:Active (exists now) ; Research Funding (PI or named investigator):Boehringer Ingelheim:Active (exists now) ; Research Funding (PI or named investigator):Bayer:Active (exists now) ; Research Funding (PI or named investigator):Amgen:Active (exists now) | Michael Shapiro: DO have relevant financial relationships ; Consultant:Amgen:Active (exists now) ; Advisor:Arrowhead:Active (exists now) ; Advisor:Merck:Active (exists now) ; Consultant:Regeneron:Active (exists now) ; Advisor:Ionis:Active (exists now) ; Advisor:Agepha:Past (completed) ; Consultant:Novartis:Active (exists now)
Meeting Info:

Scientific Sessions 2024

2024

Chicago, Illinois

Session Info:

Lp(a), Familial Hypercholesterolemia, and Lipid Lowering Therapies

Sunday, 11/17/2024 , 03:15PM - 04:15PM

Abstract Poster Session

More abstracts on this topic:
Can Machine Learning Help Prioritise Who to Screen for Elevated Lipoprotein(a) (Lp[a]) in the General Population vs a Screen all Approach? An Analysis from UK Biobank

Stevens Christophe, Barkas Fotis, Brandts Julia, Kwilasi Sunganani, Mahani Alireza, Vallejo-vaz Antonio J., Taghavi Azar Sharabiani Mansour, Ray Kausik

A Novel Tool for Evaluating Endothelial Function: Plethysmographic Flow-mediated Vasodilation (pFMD)

Kishimoto Shinji, Itarashiki Tomomasa, Higashi Yukihito, Maruhashi Tatsuya, Kajikawa Masato, Mizobuchi Aya, Harada Takahiro, Yamaji Takayuki, Nakano Yukiko, Mohamad Yusoff Farina, Yada Tomohiko

More abstracts from these authors:
The Role of Advanced Lipid Testing in 2024

Shapiro Michael, Gianos Eugenia, Taub Pam, Wilkinson Michael

Lipoprotein (a), Triglyceride-Glucose Index and Incident Atherosclerotic Cardiovascular Disease (ASCVD): Analysis of the UK Biobank

Kazibwe Richard, Bhatia Harpreet, Michos Erin, Shapiro Michael, Schaich Christopher, Chevli Parag, Kingsley Jeffrey, Rikhi Rishi, Ahmad Muhammad, Mirzai Saeid, Namutebi Juliana, Mehta Anurag

You have to be authorized to contact abstract author. Please, Login
Not Available